Viatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.
Follow VTRS
Viatris Inc. (VTRS) Shares outstanding
Viatris Inc.'s shares outstanding at the end of fiscal 2025 was $1.2B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $1.2B. Over the past ten years it has ranged from $497.4M (fiscal 2015) to $1.2B (fiscal 2022); the current reading is higher than 64% of that period. Viatris Inc. ranks 4th of 83 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $1.2B | (1.89%) |
| FY2024 | $1.2B | (1.13%) |
| FY2023 | $1.2B | (0.86%) |
| FY2022 | $1.2B | 0.71% |
| FY2021 | $1.2B | 101.06% |
| FY2020 | $601.2M | 16.40% |
| FY2019 | $516.5M | 0.00% |
| FY2018 | $516.5M | (3.76%) |
| FY2017 | $536.7M | 3.11% |
| FY2016 | $520.5M | 4.64% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $1.2B | (1.02%) |
| Mar 2026 | $1.2B | 0.39% |
| Dec 2025 | $1.2B | 0.52% |
| Sep 2025 | $1.2B | (0.72%) |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $4.6B |
| TAK Takeda Pharmaceutical Co. compare | $3.2B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $1.2B |
| VTRS Viatris Inc. | $1.2B |
| RDY Dr. Reddy's Laboratories Ltd compare | $783.3M |
| ELAN Elanco Animal Health Incorporated compare | $505.9M |
| ZTS Zoetis Inc. compare | $417.7M |
| NBIX Neurocrine Biosciences, Inc. compare | $104.2M |
| UTHR United Therapeutics Corporation compare | $45.8M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on VTRS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement